EIC and Invest-NL completed a €30m investment in Leyden Labs.

An investment firm, EIC, and Invest-NL completed a €30m investment in Leyden Labs, a clinical-stage biotechnology company developing nasal spray-based protection against respiratory viruses. “With PanFlu, we are taking a bold step to stop influenza viruses at the gate. We are proud to welcome these two esteemed European funds, each to accelerate innovations in Europe that deliver public benefit. Their support for our strategy to develop novel products to protect against respiratory viruses is a wonderful endorsement of our relentless efforts,” Koenraad Wiedhaup, Leyden Labs Co-Founder and CEO.